Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2004;29(1):1–17. doi: 10.1385/IR:29:1-3:001

Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS

Aftab A Ansari 1, Ann E Mayne 1, Nattawat Onlamoon 2, Kovit Pattanapanyasat 2, Kazuyasu Mori 3, Francois Villinger 1
PMCID: PMC7090896  PMID: 15181266

Abstract

Outbreaks of infectious diseases such as HIV and the much televised and attention-getting outbreaks of diseases such as Ebola, Hantaviruses, and the most recent outbreak of SARS have induced a significant new interest in the formulations and more importantly the science of vaccinology, which has previously to a large extent been conducted empirically. Our laboratory has focused on the use of recombinant nonhuman primate cytokines as adjunctive therapies for inducing antigen-specific immune responses in monkeys because most recombinant human cytokines appear to be immunogenic. This article provides a summary of our work with such cytokines, which includes attempts to define optimum dosing schedules that lead to optimal primary and lasting memory antigen-specific immune responses.

Key Words: Nonhuman primate, cytokines, antiviral immunity, SIV, AIDS

References

  • 1.Voss G, Villinger F. Adjuvanted vaccine strategies and live vector approaches for the prevention of AIDS. AIDS. 2000;14(Suppl 3):153–165. [PubMed] [Google Scholar]
  • 2.Villinger F. Cytokines as clinical adjuvants: how farare we? Expert Rev Vaccines. 2003;2:317–326. doi: 10.1586/14760584.2.2.317. [DOI] [PubMed] [Google Scholar]
  • 3.McClure HM, Anderson DC, Fultz PN, Ansari AA, Lockwood E, Brodie A. Spectrum of disease in macaque monkeys chronically infected with SIV/SMM. Vet Immunol Immunopathol. 1989;21:13–24. doi: 10.1016/0165-2427(89)90126-8. [DOI] [PubMed] [Google Scholar]
  • 4.Bostik P, Villinger F, Brice GT, Chikkala NF, Brar SS, Cruikshank WW, et al. Expression and in vitro evaluation of rhesus macaque wild type (wt) and modified CC chemokines. J Med Primatol. 1998;27:113–120. doi: 10.1111/j.1600-0684.1998.tb00235.x. [DOI] [PubMed] [Google Scholar]
  • 5.Villinger F, Bostik P, Mayre A, King CL, Gerain CP, Weiss WR, et al. Cloning, sequencing and homology analysis of nonhuman primate Fas/Fas-ligand and co-stimulatory molecules. Immunogenetics. 2001;53:315–328. doi: 10.1007/s002510100322. [DOI] [PubMed] [Google Scholar]
  • 6.Lee ME, Adams JW, Villinger F, Brar SS, Meadows M, Bucur SZ, et al. Molecular cloning and expression of rhesus macaque and scoty mangabey interleukin 16: biologic activity and effect on simian immunodeficiency virus infection and/or replication. AIDS Res Hum Retroviruses. 1998;14:1323–1328. doi: 10.1089/aid.1998.14.1323. [DOI] [PubMed] [Google Scholar]
  • 7.Villinger F, Brar SS, Mayne A, Chikkala N, Ansari AA. Comparative sequence analysis of cytokine genes from human and non human primates. J Immunol. 1995;155:3946–3954. [PubMed] [Google Scholar]
  • 8.Hutchinson KL, Villinger F, Miranda ME, Ksiazek TG, Peters CJ, Rollin PE. Multiplex analysis of cytokines in the blood of cynomolgus macaques naturally infected with Ebola virus (Reston serotype) J Med Virol. 2001;65:561–566. doi: 10.1002/jmv.2073. [DOI] [PubMed] [Google Scholar]
  • 9.Villinger F, Hunt D, Mayne A, Vuchetich M, Findley H, Ansari AA. Qualitative and quantitative studies of cytokines synthesized and secreted by non-human primate peripheral blood mononuclear cells. Cytokine. 1993;5:469–479. doi: 10.1016/1043-4666(93)90038-7. [DOI] [PubMed] [Google Scholar]
  • 10.Makitalo B, Andersson M, Arestrom I, Karlen K, Villinger F, Ansari A, et al. ELISpot and ELISA analysis of spontaneous, mitogen-induced and antigen-specific cytokine production in cynomolgus and rhesus macaques. J Immunol Methods. 2002;270:85–97. doi: 10.1016/s0022-1759(02)00274-0. [DOI] [PubMed] [Google Scholar]
  • 11.Ullenhag G, Bird C, Ragnhammar P, Frodin JE, Strigard K, Olsterborg A, et al. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation. Clin Immunol. 2001;99:65–74. doi: 10.1006/clim.2000.4999. [DOI] [PubMed] [Google Scholar]
  • 12.Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133–146. doi: 10.1038/nri1001. [DOI] [PubMed] [Google Scholar]
  • 13.Gherardi MM, Ramirez JC, Esteban M. Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. Histol Histopathol. 2001;16:655–667. doi: 10.14670/HH-16.655. [DOI] [PubMed] [Google Scholar]
  • 14.Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13:155–168. doi: 10.1016/S1359-6101(01)00032-6. [DOI] [PubMed] [Google Scholar]
  • 15.Hoffman SL, Crutcher JM, Puri SK, Ansari AA, Villinger F, Franke ED, et al. Sterile protection of monkeys against malaria after administration of interleukin-12. Nat Med. 1997;3:80–83. doi: 10.1038/nm0197-80. [DOI] [PubMed] [Google Scholar]
  • 16.Villinger F, Bucur S, Chikkala NF, Brar SS, Bostik P, Mayne AE, et al. In vitro and in vivo responses to interleukin 12 are maintained until the late SIV infection stage but lost during AIDS. AIDS Res Hum Retroviruses. 2000;16:751–763. doi: 10.1089/088922200308756. [DOI] [PubMed] [Google Scholar]
  • 17.Gazzinelli RT, Giese NA, Morse HC., III In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS) J Exp Med. 1994;180:2199–2208. doi: 10.1084/jem.180.6.2199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Rakhit A, Yeon MM, Ferrante J, Fettner S, Nadeau R, Motzer R, et al. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this “adaptive response” in mice. Clin Pharmacol Ther. 1999;65:615–629. doi: 10.1016/S0009-9236(99)90083-8. [DOI] [PubMed] [Google Scholar]
  • 19.Wang KS, Zorn E, Ritz J. Specific down-regulation of interlekin-12 signaling through induction of phospho-STAT4 protein degradation. Blood. 2001;97:3860–3866. doi: 10.1182/blood.V97.12.3860. [DOI] [PubMed] [Google Scholar]
  • 20.Wang KS, Ritz J, Frank DA. IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells. J Immunol. 1999;162:299–304. [PubMed] [Google Scholar]
  • 21.Uzel G, Frucht DM, Fleisher TA, Holland SM. Detection of intracellular phosphorylated STAT-4 by flow cytometry. Clin Immunol. 2001;100:270–276. doi: 10.1006/clim.2001.5078. [DOI] [PubMed] [Google Scholar]
  • 22.Ansari AA, Mayne AE, Sundstrom JB, Bostik P, Grimm B, Altman JD, et al. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIV mac251-infected rhesus macaques. J Virol. 2002;76:1731–1743. doi: 10.1128/JVI.76.4.1731-1743.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Villinger F, Brice GT, Mayne AE, Bostik P, Mori K, June CH, et al. Adoptive transfer of simian immunodeficiency virus (SIV) naive autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status. Blood. 2002;99:590–599. doi: 10.1182/blood.V99.2.590. [DOI] [PubMed] [Google Scholar]
  • 24.van der Meide PH, Villinger F, Ansari AA, Groenestein RJ, de Labie MC, van den Hout YJ, et al. Stimulation of both humoral and cellular immune responses to HIV-1 gpl 20 by interleukin-12 in Rhesus macaques. Vaccine. 2002;20:2296–2302. doi: 10.1016/S0264-410X(02)00101-9. [DOI] [PubMed] [Google Scholar]
  • 25.O'Neill E, Martinez I, Villinger F, Rivera M, Gascot S, Colon C, et al. Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. J Med Primatol. 2002;31:217–227. doi: 10.1034/j.1600-0684.2002.02008.x. [DOI] [PubMed] [Google Scholar]
  • 26.Kumar S, Villinger F, Oakley M, Aguiar JC, Jones TR, Hedstrom RC, et al. A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophagecolony stimulating factor. Immunol Lett. 2002;81:13–24. doi: 10.1016/S0165-2478(01)00316-9. [DOI] [PubMed] [Google Scholar]
  • 27.Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by co-inoculation with plasmids expressing cytokines. Immunity. 1995;2:129–135. doi: 10.1016/S1074-7613(95)80001-8. [DOI] [PubMed] [Google Scholar]
  • 26.Kusakabe K, Xin KQ, Katoh H, Sumino K, Hagiwara E, Kawamoto S, et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol. 2000;164:3102–3111. doi: 10.4049/jimmunol.164.6.3102. [DOI] [PubMed] [Google Scholar]
  • 28.Lena P, Villinger F, Giavedoni L, Miller CJ, Rhodes G, Luciw P. Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus. Vaccine. 2002;20(Suppl 4):A69–79. doi: 10.1016/S0264-410X(02)00391-2. [DOI] [PubMed] [Google Scholar]
  • 30.Lehner T, Wang Y, Cranage M, Tao L, Mitchell E, Bravery C, et al. Up-regulation of beta-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in non-human primates. Immunology. 2000;99:569–577. doi: 10.1046/j.1365-2567.2000.00993.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity. 2001;14:105–110. [PubMed] [Google Scholar]
  • 32.Villinger F, Miller R, Mori K, Mayne AE, Bostik P, Sundstrom JB, et al.: IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques. Vaccines, 2004, In press. [DOI] [PubMed]
  • 33.Smith KA. Low-dose daily interleukin-2 immunotherapy: accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity. AIDS. 2001;15(Suppl 2):28–35. doi: 10.1097/00002030-200102002-00006. [DOI] [PubMed] [Google Scholar]
  • 34.Davey RT, Jr., Chaitt DG, Albert JM, Piscitellii SC, Kovacs JA, Walker RE, et al. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis. 1999;179:849–858. doi: 10.1086/314678. [DOI] [PubMed] [Google Scholar]
  • 35.Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP. Coadministration of HIV vaccine vectors with vacinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci USA. 2003;100:3392–3397. doi: 10.1073/pnas.0630592100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Kikkawa S, Shida K, Okamura H, Begum NA, Matsumoto M, Tsuji S, et al. A comparative analysis of the antigenic, structural, and functional properties of three different preparations of recombinant human interleukin-18. J Interferoin Cytokine Res. 2000;20:179–185. doi: 10.1089/107999000312586. [DOI] [PubMed] [Google Scholar]
  • 37.Giavedoni LD, Velasquillo MC, Parodi LM, Hubbard GB, Hodara VL. Expression of IL-18 by SIV does not modify the outcome of the antiviral immune response. Virology. 2002;303:327–337. doi: 10.1006/viro.2002.1647. [DOI] [PubMed] [Google Scholar]
  • 38.Liu B, Novick D, Kim SH, Rubinstein M. Production of a biologically active human interleukin 18 requires its prior synthesis as PRO-IL-18. Cytokine. 2000;12:1519–1525. doi: 10.1006/cyto.2000.0749. [DOI] [PubMed] [Google Scholar]
  • 39.Gadina M, Ferguson PR, Johnston JA. New interleukins: are there any more? Curr Opin Infect Dis. 2003;16:211–217. doi: 10.1097/00001432-200306000-00005. [DOI] [PubMed] [Google Scholar]
  • 40.Harandi AM, Eriksson K, Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol. 2003;77:953–962. doi: 10.1128/JVI.77.2.953-962.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Vandenbroeck K, Goris A. Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy? Trends Pharmacol Sci. 2003;24:284–289. doi: 10.1016/S0165-6147(03)00131-7. [DOI] [PubMed] [Google Scholar]

Articles from Immunologic Research are provided here courtesy of Nature Publishing Group

RESOURCES